Detalles de la búsqueda
1.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33684370
2.
Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases.
Support Care Cancer
; 26(6): 1897-1903, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29275524
3.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Eur J Cancer
; 183: 24-37, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36796234
4.
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Eur J Cancer
; 141: 21-29, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125944
5.
Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Radiother Oncol
; 150: 18-25, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32417348
Resultados
1 -
5
de 5
1
Próxima >
>>